Quotient Bioresearch’s new Radiochemistry Facility Fully Operational
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Quotient Bioresearch has announced that its new radiochemistry facility in Cardiff, UK is fully operational and that shipments of radiolabelled products have commenced.
All staff have successfully transferred from the former site operated by Amersham Radiolabelling Services to the new facility.
The new facility, located close to Cardiff Bay, represents a significant investment by Quotient and follows the Company's acquisition of Amersham Radiolabelling Services from GE Healthcare in June 2009. The facility has been named "The Old Glassworks", reflecting the origins of the site on which it was built.
The Old Glassworks will produce radiolabelled compounds for its pharmaceutical, biotechnology and agrochemical clients, offering an established bespoke service for the custom synthesis of carbon-14 and tritium labelled compounds. Quotient's capabilities allow it to manufacture custom radiolabelled drugs for use in both pre-clinical and clinical settings.
Quotient offers its clients a range of services including custom radiosynthesis services and carbon-14-enabled drug development. With its strong existing client base in Europe, the United States and Japan, Quotient will serve over 250 clients worldwide from The Old Glassworks. Its chemists work closely with the company's metabolism and clinical research groups to deliver clients solution for their carbon-14 enabled drug development needs.
The Old Glassworks has been equipped with world-class technology, operating to the highest environmental and safety standards. It houses the largest and an experienced team of radiosynthesis chemists and brings the total number of Quotient employees to over 600.
All staff have successfully transferred from the former site operated by Amersham Radiolabelling Services to the new facility.
The new facility, located close to Cardiff Bay, represents a significant investment by Quotient and follows the Company's acquisition of Amersham Radiolabelling Services from GE Healthcare in June 2009. The facility has been named "The Old Glassworks", reflecting the origins of the site on which it was built.
The Old Glassworks will produce radiolabelled compounds for its pharmaceutical, biotechnology and agrochemical clients, offering an established bespoke service for the custom synthesis of carbon-14 and tritium labelled compounds. Quotient's capabilities allow it to manufacture custom radiolabelled drugs for use in both pre-clinical and clinical settings.
Quotient offers its clients a range of services including custom radiosynthesis services and carbon-14-enabled drug development. With its strong existing client base in Europe, the United States and Japan, Quotient will serve over 250 clients worldwide from The Old Glassworks. Its chemists work closely with the company's metabolism and clinical research groups to deliver clients solution for their carbon-14 enabled drug development needs.
The Old Glassworks has been equipped with world-class technology, operating to the highest environmental and safety standards. It houses the largest and an experienced team of radiosynthesis chemists and brings the total number of Quotient employees to over 600.
